Angelini et al. showed how FLT3ITDmut AML cells express the CD34+/CD25+/CD123+/CD99+ phenotype, identifying CD99 and CD123 as possible targets for immunotherapy [10]. This evidence concerns the gene CD99 and acute myeloid leukemia.